Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications - PubMed (original) (raw)
Review
. 2015 Mar 2;4(4):e1008814.
doi: 10.1080/2162402X.2015.1008814. eCollection 2015 Apr.
Norma Bloy 2, Fernando Aranda 3, Francesca Castoldi 4, Alexander Eggermont 5, Isabelle Cremer 6, Wolf Hervé Fridman 7, Jitka Fucikova 8, Jérôme Galon 9, Aurélien Marabelle 10, Radek Spisek 11, Eric Tartour 12, Laurence Zitvogel 10, Guido Kroemer 13, Lorenzo Galluzzi 14
Affiliations
- PMID: 26137403
- PMCID: PMC4485728
- DOI: 10.1080/2162402X.2015.1008814
Review
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Aitziber Buqué et al. Oncoimmunology. 2015.
Abstract
Immunomodulatory monoclonal antibodies (mAbs) differ from their tumor-targeting counterparts because they exert therapeutic effects by directly interacting with soluble or (most often) cellular components of the immune system. Besides holding promise for the treatment of autoimmune and inflammatory disorders, immunomodulatory mAbs have recently been shown to constitute a potent therapeutic weapon against neoplastic conditions. One class of immunomodulatory mAbs operates by inhibiting safeguard systems that are frequently harnessed by cancer cells to establish immunological tolerance, the so-called "immune checkpoints." No less than 3 checkpoint-blocking mAbs have been approved worldwide for use in oncological indications, 2 of which during the past 12 months. These molecules not only mediate single-agent clinical activity in patients affected by specific neoplasms, but also significantly boost the efficacy of several anticancer chemo-, radio- or immunotherapies. Here, we summarize recent advances in the development of checkpoint-blocking mAbs, as well as of immunomodulatory mAbs with distinct mechanisms of action.
Keywords: CRC, colorectal carcinoma; CTLA4, cytotoxic T lymphocyte-associated protein 4; FDA, Food and Drug Administration; IL, interleukin; KIR, killer cell immunoglobulin-like receptor; MEDI4736; MPDL3280A; NK, natural killer; NSCLC, non-small cell lung carcinoma; PD-1, programmed cell death 1; RCC, renal cell carcinoma; TGFβ1, transforming growth factor β1; TLR, Toll-like receptor; TNFRSF, tumor necrosis factor receptor superfamily; Treg, regulatory T cell; ipilimumab; mAb, monoclonal antibody; nivolumab; pembrolizumab; urelumab.
Similar articles
- Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Aranda F, et al. Oncoimmunology. 2014 Jan 1;3(1):e27297. doi: 10.4161/onci.27297. Epub 2014 Feb 1. Oncoimmunology. 2014. PMID: 24701370 Free PMC article. - Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Oncoimmunology. 2015 Feb 3;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. Oncoimmunology. 2015. PMID: 25949870 Free PMC article. Review. - Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L. Cabo M, et al. Oncoimmunology. 2017 Aug 30;6(12):e1371896. doi: 10.1080/2162402X.2017.1371896. eCollection 2017. Oncoimmunology. 2017. PMID: 29209572 Free PMC article. Review. - The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM, Freeman GJ, McDermott DF. Mahoney KM, et al. Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review. - Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y, Gao S, Gou J, Yin T, He H, Wang Y, Zhang Y, Tang X, Wu R. Xue Y, et al. Expert Opin Drug Deliv. 2021 Feb;18(2):187-203. doi: 10.1080/17425247.2021.1825376. Epub 2020 Oct 5. Expert Opin Drug Deliv. 2021. PMID: 32954856 Review.
Cited by
- Digital Pathology for Better Clinical Practice.
Hijazi A, Bifulco C, Baldin P, Galon J. Hijazi A, et al. Cancers (Basel). 2024 Apr 26;16(9):1686. doi: 10.3390/cancers16091686. Cancers (Basel). 2024. PMID: 38730638 Free PMC article. Review. - Principles of risk assessment in colon cancer: immunity is key.
Hijazi A, Galon J. Hijazi A, et al. Oncoimmunology. 2024 Apr 30;13(1):2347441. doi: 10.1080/2162402X.2024.2347441. eCollection 2024. Oncoimmunology. 2024. PMID: 38694625 Free PMC article. Review. - Structure and function of therapeutic antibodies approved by the US FDA in 2023.
Strohl WR. Strohl WR. Antib Ther. 2024 Mar 19;7(2):132-156. doi: 10.1093/abt/tbae007. eCollection 2024 Apr. Antib Ther. 2024. PMID: 38617189 Free PMC article. Review. - Multi-Institutional Evaluation of Pathologists' Assessment Compared to Immunoscore.
Willis J, Anders RA, Torigoe T, Hirohashi Y, Bifulco C, Zlobec I, Mlecnik B, Demaria S, Choi WT, Dundr P, Tatangelo F, Di Mauro A, Baldin P, Bindea G, Marliot F, Haicheur N, Fredriksen T, Kirilovsky A, Buttard B, Vasaturo A, Lafontaine L, Maby P, El Sissy C, Hijazi A, Majdi A, Lagorce C, Berger A, Van den Eynde M, Pagès F, Lugli A, Galon J. Willis J, et al. Cancers (Basel). 2023 Aug 10;15(16):4045. doi: 10.3390/cancers15164045. Cancers (Basel). 2023. PMID: 37627073 Free PMC article. - Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.
Hijazi A, Antoniotti C, Cremolini C, Galon J. Hijazi A, et al. Oncoimmunology. 2023 Aug 5;12(1):2243169. doi: 10.1080/2162402X.2023.2243169. eCollection 2023. Oncoimmunology. 2023. PMID: 37554310 Free PMC article. Review.
References
- Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, et-al.. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383–95; PMID:; http://dx.doi.org/10.1056/NEJMoa0904492 - DOI - PubMed
- Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et-al.. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343:1594–602; PMID:; http://dx.doi.org/10.1056/NEJM200011303432202 - DOI - PubMed
- Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA.. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997–1008; PMID:; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214 - DOI - PubMed
- Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L.. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106; PMID:; http://dx.doi.org/10.1038/nrc2051 - DOI - PubMed
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:; http://dx.doi.org/10.1038/nrc3239 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous